Characteristic of the study participants
| All (n=241) | Sitagliptin (n=120) | Voglibose (n=121) | p Value | |
|---|---|---|---|---|
| Male/Female | 143/98 | 72/48 | 71/50 | 0.603 |
| Age (years) | 63.2±12.7 | 63.2±13.8 | 63.2±11.6 | 0.699 |
| Medication adherence rate (≥80%/<80%) | 193/48 | 99/21 | 94/27 | 0.420 |
| Combination therapy (Diet/SU/BG/TZD) | 116/61/57/7 | 59/29/29/3 | 57/32/28/4 | 0.953 |
| Body weight (kg) | 64.8±14.4 | 63.8±13.6 | 65.8±15.1 | 0.515 |
| BMI (kg/m2) | 25.0±4.5 | 25.0±4.5 | 25.1±4.5 | 0.984 |
| Waist circumference (cm) | 89.9±11.1 | 88.7±10.5 | 91.0±11.7 | 0.162 |
| Systolic BP (mm Hg) | 130.8±17.7 | 130.0±16.8 | 131.6±18.5 | 0.413 |
| FPG (mg/dL) | 154.7±35.1 | 156.3±35.1 | 153.2±35.2 | 0.347 |
| HbA1c (%) | 7.9±0.9 | 7.9±1.0 | 7.8±0.8 | 0.935 |
| 1.5AG (μg/mL) | 6.9±4.8 | 6.5±4.2 | 7.4±5.3 | 0.429 |
| BUN (mg/dL) | 15.1±4.5 | 14.9±4.1 | 15.2±4.9 | 0.886 |
| s-Cre (mg/dL) | 0.72±0.23 | 0.70±0.19 | 0.74±0.27 | 0.870 |
| AST (IU/L) | 26±14 | 26±13 | 26±16 | 0.823 |
| ALT (IU/L) | 31±25 | 32±25 | 30±25 | 0.522 |
| γ-GTP (IU/L) | 46±53 | 44±49 | 49±57 | 0.072 |
| TC (mg/dL) | 188.4±33.0 | 185.1±33.4 | 191.6.±32.4 | 0.130 |
| TG (mg/dL) | 140.1±93.6 | 136.0±83.1 | 144.2±103.1 | 0.899 |
| HDL-C (mg/dL) | 53.8±16.7 | 52.7±15.4 | 54.9±18.0 | 0.250 |
| LDL-C (mg/dL) | 106.2±28.1 | 105.0±29.6 | 107.5±26.5 | 0.234 |
Data are expressed as means±SD. p Value for the intergroup comparison.
AG, anhydroglucitol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BG, biguanide; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-c, low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein-cholesterol; s-Cre, serum creatinine; SU, sulfonylurea; TC, total cholesterol; TG, triglyceride; TZD, thiazolidinedione; γ-GTP, γ-glutamyl transpeptidase.